CELLECT BIOTECH/S (APOP) Getting Somewhat Favorable Media Coverage, Study Shows

Media stories about CELLECT BIOTECH/S (NASDAQ:APOP) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CELLECT BIOTECH/S earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.3583768207142 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of research analysts have weighed in on APOP shares. Zacks Investment Research downgraded CELLECT BIOTECH/S from a “buy” rating to a “hold” rating in a research note on Wednesday, April 4th. ValuEngine upgraded CELLECT BIOTECH/S from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of CELLECT BIOTECH/S in a research note on Tuesday, May 29th.

Get CELLECT BIOTECH/S alerts:

CELLECT BIOTECH/S traded down $0.04, reaching $7.15, during mid-day trading on Friday, MarketBeat Ratings reports. The company had a trading volume of 1,435 shares, compared to its average volume of 16,930. The company has a market cap of $39.11 million, a price-to-earnings ratio of -4.90 and a beta of 4.66. CELLECT BIOTECH/S has a 52 week low of $6.12 and a 52 week high of $13.50.

CELLECT BIOTECH/S (NASDAQ:APOP) last posted its quarterly earnings results on Thursday, May 17th. The company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.14. equities analysts forecast that CELLECT BIOTECH/S will post -1 EPS for the current fiscal year.

About CELLECT BIOTECH/S

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Insider Buying and Selling by Quarter for CELLECT BIOTECH/S (NASDAQ:APOP)